(Q39170011)

9 September 2017

title

Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities (English)

1 reference

9 September 2017

0 references

Vijayendra Dasari

1

1 reference

9 September 2017

Kunal H Bhatt

series ordinal

2

1 reference

9 September 2017

Corey Smith

series ordinal

3

1 reference

9 September 2017

Rajiv Khanna

series ordinal

4

1 reference

9 September 2017

publication date

20 February 2017

1 reference

Expert Review of Vaccines

9 September 2017

published in

1 reference

9 September 2017

volume

16

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

377-390

1 reference

Progress and problems in understanding and managing primary Epstein-Barr virus infections

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus: an important vaccine target for cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-barr virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The immunology of Epstein-Barr virus-induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus and Burkitt lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The Epstein-Barr virus and its association with human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Nasopharyngeal carcinoma: treatments and outcomes in the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus infections: prospects for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Innate immune responses against Epstein Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Cytokine-Mediated Loss of Blood Dendritic Cells During Epstein-Barr Virus-Associated Acute Infectious Mononucleosis: Implication for Immune Dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus-encoded LMP1 promotes cisplatin-induced caspase activation through JNK and NF-kappaB signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Animal models of Epstein Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Neutralizing antibodies to Epstein-Barr virus in healthy populations and patients with infectious mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Long-term T-cell-mediated immunity to epstein-barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Long-term T-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Therapeutic vaccination strategies to treat nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Immunotherapy for nasopharyngeal cancer-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Characterization of an Epstein-Barr virus receptor on human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Different functional domains in the cytoplasmic tail of glycoprotein B are involved in Epstein-Barr virus-induced membrane fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A virus-like particle-based Epstein-Barr virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Generating functional CD8+ T cell memory response under transient CD4+ T cell deficiency: implications for vaccination of immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Progress, prospects, and problems in Epstein-Barr virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

B cell-derived circulating granzyme B is a feature of acute infectious mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Understanding human T-cell-mediated immunoregulation through herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Direct immunosuppressive effects of EBV-encoded latent membrane protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Lifelong persistent EBV infection of rabbits with EBER1-positive lymphocyte infiltration and mild sublethal hemophagocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A new animal model for primary and persistent Epstein-Barr virus infection: human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Development of a human adaptive immune system in cord blood cell-transplanted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

The need and challenges for development of an Epstein-Barr virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

Characteristics of Hodgkin's Lymphoma after Infectious Mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1293529

10.1080/14760584.2017.1293529

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference